<?xml version="1.0" encoding="UTF-8"?>
<p>Nowadays, using a combination therapy of protease inhibitors with reverse transcriptase inhibitors, called highly active antiretroviral therapy (HAART), significantly enhanced the clinical outcome, reduced mortality, and morbidity, and greatly improved the life expectancy in HIV-1-infected individuals. HAART cannot eradicate the virus from HIV-infected cases. Drug-resistant, long-term use toxicity, and related high-cost limit the use of HAART in infected individuals (
 <xref rid="B211" ref-type="bibr">Simon et al., 2006</xref>). These all raise the need for novel medicinal agents (
 <xref rid="B109" ref-type="bibr">Kitazato et al., 2007</xref>).
</p>
